Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  • End date
    Jun 23, 2029
  • participants needed
  • sponsor
    ITM Solucin GmbH
Updated on 23 September 2021
measurable disease
progressive disease
radionuclide therapy


The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Condition Neuroendocrine Tumor, Neuroectodermal Tumor, Neurectoderma, neuroendocrine tumors, neuroendocrine tumour
Treatment Everolimus, 177Lu-edotreotide PRRT, Amino-Acid Solution
Clinical Study IdentifierNCT03049189
SponsorITM Solucin GmbH
Last Modified on23 September 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET)
Measurable disease per RECIST 1.1
Somatostatin receptor positive (SSTR+) disease
Progressive disease based on RECIST 1.1. criteria as evidenced by two morphological imaging examinations made with the same imaging method (either CT or MRI)

Exclusion Criteria

Known hypersensitivity to edotreotide or everolimus
Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative
Prior exposure to any peptide receptor radionuclide therapy (PRRT)
Prior therapy with mTor inhibitors
Prior EFR (external field radiation) to GEP-NET lesions within 90 days before randomisation or radioembolisation therapy
Therapy with an investigational compound and/or medical device within 30 days prior to randomisation
Indication for surgical lesion removal with curative potential
Planned alternative therapy (for the period of study participation)
Serious non-malignant disease
Clinically relevant renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments
Pregnant or breast-feeding women
Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) or any other vulnerable population to that sense (e.g. persons institutionalised, incarcerated etc.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note